Effects of captopril and enalapril on zinc metabolism in hypertensive patients

J Am Coll Nutr. 1998 Feb;17(1):75-8. doi: 10.1080/07315724.1998.10720459.


Objective: To investigate the effect of chronic captopril and enalapril treatment on zinc metabolism in hypertensive patients by assessing zinc levels in serum, urine and monocytes.

Methods: Patients with newly diagnosed essential hypertension were randomly divided into two treatment groups: those treated with captopril only (n = 16) and those treated with enalapril only (n = 18). Ten healthy subjects served as controls. Prior to the start of treatment and again 6 months later, zinc was assessed in the serum, in urine collected over 24 hours, and in peripheral blood monocytes.

Results: Significant enhancement of 24-hour urinary zinc excretion (micrograms/24 hour) after 6 months of treatment was observed only in the captopril-treated group (p < 0.01). However, intramonocytic zinc levels decreased significantly in both of the treated groups over the same period (p < 0.01 and P < 0.04 in the captopril- and enalapril-treated groups, respectively).

Conclusion: Treatment of hypertensive patients with captopril or enalapril may result in zinc deficiency.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / therapeutic use
  • Captopril / adverse effects*
  • Captopril / therapeutic use
  • Enalapril / adverse effects*
  • Enalapril / therapeutic use
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Male
  • Monocytes / metabolism*
  • Prospective Studies
  • Zinc / blood
  • Zinc / metabolism*
  • Zinc / urine


  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Enalapril
  • Captopril
  • Zinc